A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome

Inclusion Criteria: * Age≥18; * The diagnosis of MDS patients comply WHO2008 standards; * IPSS score≥0.5; * WHO classification for patients RCUD, RARS and transfusion-dependent RCMD; * ECOG PS score: 0-2; * Expected survival≥3 months; * Serum bilirubin≤1.5\*ULN, serum ALT and AST≤2.5\*ULN, serum Cr≤1.5\*ULN; * Subjects signed informed consent form in line with GCP requirements. Exclusion Criteria: * Can not marrow biopsy; * Previously diagnosed AML; * Received azacitidine or decitabine treatment any time before; * Being diagnosed with other malignancies in the prior 12 months; * Pregnant or lactating women; * Failure to control systemic fungal, bacterial or viral infection; * Known or suspected allergy to decitabine; * Known human immunodeficiency virus (HIV) or hepatitis B or C classes of active viral infection; * Have a history of neurological or psychiatric disorders, including epilepsy or dementia; * CTCAE 3 or 4 degree peripheral neuropathy; * According to the investigator's judgment, there are concomitant diseases with a serious safety hazard or affect the patients completed the study in patients; * Using other experimental drugs or participating in other clinical trials in the prior one months.